Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19010250 | 0.86 | MAP4K4 (0.38) | MAP4K4EPHX1KEAP1NFE2L2 | |
| SCHEMBL19010255 | 0.83 | SMN1; SMN2 (0.41) | EPHX1HPGDKMT2AKEAP1NFE2L2 | |
| SCHEMBL18502528 | 0.81 | POLB (0.41) | ALDH1A1BRD4LMNAEPHX1HPGD | |
| SCHEMBL18506005 | 0.79 | ALDH1A1 (0.32) | ALDH1A1MCL1LMNAMAP4K4 | |
| SCHEMBL13255642 | 0.79 | KEAP1 (0.43) | MAP4K4EPHX1HPGDKMT2AKEAP1 | |
| SCHEMBL17082787 | 0.79 | CHRNB2 (0.41) | ALDH1A1MAP4K4EPHX1 | |
| SCHEMBL19022017 | 0.79 | KMT2A (0.38) | MCL1KMT2AGAAKEAP1NFE2L2 | |
| SCHEMBL26272048 | 0.78 | BRD4 (0.31) | BRD4 | |
| SCHEMBL18389826 | 0.78 | CHRM5 (0.40) | ALDH1A1KMT2A | |
| SCHEMBL104261 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| EP-4248968-A2 | TLR7/8 ANTAGONISTS AND USES THEREOF | Merck Patent GmbH (DE) | 2023-09-27 | — | — | EP | disclosed |
| EP-3655401-B1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-06 | — | — | EP | disclosed |
| US-10793553-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2020-10-06 | — | — | US | disclosed |
| WO-2020025517-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-02-06 | — | — | WO | disclosed |
| US-20190023687-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-01-24 | — | — | US | disclosed |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | ALDH1A1 2648/4885BRD4 970/4885MCL1 471/4885 |
| US-20190023687-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | ALDH1A1 2465/4885BRD4 1142/4885MCL1 698/4885 |
| US-10793553-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | ALDH1A1 2465/4885BRD4 1142/4885MCL1 698/4885 |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | ALDH1A1 2465/4885BRD4 1142/4885MCL1 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.